Parathyroid hormone therapy for osteoporosis
Teriparatide is a new and different drug as a treatment for osteoporosis. It works to increase new bone formation. Teriparatide is a man-made recombinant parathyroid hormone that has an amino acid sequence identical to part of the human parathyroid hormone (PTH). This drug has been approved by the US FDA in 2001. It is used to treat post-menopausal women with osteoporosis, men with hypogonadal or idiopathic osteoporosis, and men and women with glucocorticoid-induced osteoporosis who are at high risk for fracture.
Various anti-resorptive treatments for osteoporosis are available, but the only effective available therapy for osteoporosis is teriparatide which ease to stimulates the bone growth, slows the rate of bone loss and increases the formation of new bone tissue. As a consequence, the approved lifetime duration of treatment with teriparatide is 24 months.
Teriparatide have reported positive effects in two distinct manners. The first is direct stimulation of bone formation that occurs within active remodeling sites (remodeling-based bone formation) and on surfaces of bone previously inactive (modeling-based bone formation). The second is an increase in the initiation of new remodeling sites. Both processes contribute to the final increase in bone density observed by non-invasive tools such as DXA.
Fracture healing is a complex event that involves the coordination of a variety of different processes. Bone remodeling is the process of bone renewal which keeps bones strong, and in this way skeletal tissue is maintained in a young healthy state. Therefore, it seems that Teriparatide minimise the risk of fracture and come to light that this component increase this positive effect with long term therapy.
Teriparatide, anabolic agent stimulates osteoblastic bone formation to improve bone quality and bone mass and the study findings showed that full continuous 24-month course with teriparatide results in improved skeletal health and outcomes than shorter time periods.